Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 173

The DOI matches its Crossref record.

4‐n‐butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation

Kolbe, L., Mann, T., Gerwat, W., Batzer, J., Ahlheit, S., Scherner, C., Wenck, H., Stäb, F. · 2013 · Journal of the European Academy of Dermatology and Venereology

Abstract

Background Hyperpigmentary disorders like melasma, actinic and senile lentigines are a major cosmetic concern. Therefore, many topical products are available, containing various active ingredients aiming to reduce melanin production and distribution. The most prominent target for inhibitors of hyperpigmentation is tyrosinase, the key regulator of melanin production. Many inhibitors of tyrosinase are described in the literature; however, most of them lack clinical efficacy. Methods We were interested in evaluating the inhibition of skin pigmentation by well‐known compounds with skin‐whitening activity like hydroquinone, arbutin, kojic acid and 4‐n‐butylresorcinol. We compared the inhibition of human tyrosinase activity in a biochemical assay as well as inhibition of melanin production in MelanoDerm™ skin model culture. For some compounds, the in vivo efficacy was tested in clinical studies. Results Arbutin and hydroquinone only weakly inhibit human tyrosinase with a half maximal inhibitory concentration (IC 50) in the millimolar range. Kojic acid is 10 times more potent with an IC 50 of approximately 500 μmol/L. However, by far the most potent inhibitor of human tyrosinase is 4‐n‐butylresorcinol with an IC 50 of 21 μmol/L. In artificial skin models, arbutin was least active with an IC 50 for inhibition of melanin production > 5000 μmol/L. Kojic acid inhibited with an IC 50 > 400 μmol/L. Interestingly, hydroquinone inhibited melanin production in MelanoDerms with an IC 50 below 40 μmol/L, probably due to a mechanism different from tyrosinase inhibition. Again, 4‐n‐butylresorcinol was the most potent inhibitor with an IC 50 of 13.5 μmol/L. In vivo efficacy of 4‐n‐butyl‐resorcinol was confirmed in clinical studies. Subjects with age spots on the forearm treated twice daily two age spots with a formula containing 4‐n‐butylresorcinol and two control age spots with the corresponding vehicle. Within 8 weeks, 4‐n‐butylresorcinol reduced visibly the appearance of age spots, while the control spots showed no improvement. A second study showed that 4‐butylresorcinol was more effective than 4‐hexylresorcinol and 4‐phenylethylresorcinol. Conclusion The present in vitro and in vivo data prove the high inhibitory capacity of 4‐n‐butylresorcinol on human tyrosinase activity, exceeding by far the potency of hydroquinone, arbutin and kojic acid. The resulting clinical improvement of skin hyperpigmentations reveals 4‐n‐butylresorcinol as a very valuable active compound for the management of pigmentation disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jdv.12051

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 173

Metadata

Authors
Kolbe, L., Mann, T., Gerwat, W., Batzer, J., Ahlheit, S., Scherner, C., Wenck, H., & Stäb, F.
Venue
Journal of the European Academy of Dermatology and Venereology
Publisher
Wiley
Published
2012-12-03
Volume
27
Issue
s1
Pages
19-23
ISSN
  • 0926-9959 (ISSN-L)
  • 1468-3083
OpenAlex
W1550461747
Cited by
173
References
0
FWCI
3.36
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 4‐n‐butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation. https://app.cochat.ai/papers/10.1111/jdv.12051
The paper
Kolbe, L., Mann, T., Gerwat, W., Batzer, J., Ahlheit, S., Scherner, C., Wenck, H., & Stäb, F. (2013). 4‐n‐butylresorcinol, a highly effective tyrosinase inhibitor for the topical treatment of hyperpigmentation. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.12051

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.